{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:23:01Z","timestamp":1775168581247,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10840-021-00961-9","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T06:17:20Z","timestamp":1613715440000},"page":"165-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Benefits of cardiac pacing in ICD recipients with hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5511-6954","authenticated-orcid":false,"given":"Diego","family":"Jim\u00e9nez-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Castro-Urda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Toquero-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Alejandra","family":"Restrepo-C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eusebio","family":"Garc\u00eda-Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darwin","family":"Veloza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Baena-Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Garc\u00eda-Pav\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Fern\u00e1ndez-Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"961_CR1","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1056\/NEJMra022783","volume":"349","author":"BJ Maron","year":"2003","unstructured":"Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064\u201375.","journal-title":"N Engl J Med"},{"key":"961_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJM200002103420601","volume":"342","author":"BJ Maron","year":"2000","unstructured":"Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365\u201373.","journal-title":"N Engl J Med"},{"key":"961_CR3","first-page":"405","volume":"298","author":"BJ Maron","year":"2007","unstructured":"Maron BJ, Spirito P, Shen WK, Hass TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405\u201312.","journal-title":"JAMA"},{"key":"961_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJM199703133361107","volume":"336","author":"P Spirito","year":"1997","unstructured":"Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775\u201385.","journal-title":"N Engl J Med"},{"key":"961_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1106468","volume":"366","author":"JH Kim","year":"2012","unstructured":"Kim JH, Malhotra R, Chiampas G, d\u2019Hemecourt P, Troyanos C, Cianca J, et al. Cardiac arrest during long-distance running races. N Engl J Med. 2012;366:130\u201340.","journal-title":"N Engl J Med"},{"key":"961_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/CIRCHEARTFAILURE.112.969626","volume":"5","author":"AF Schinkel","year":"2012","unstructured":"Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta- analysis. Circ Heart Fail. 2012;5:552\u20139.","journal-title":"Circ Heart Fail"},{"key":"961_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.21037\/acs.2017.07.05","volume":"6","author":"N Wang","year":"2017","unstructured":"Wang N, Xie A, Tjahjono R, Tian DH, Phan S, Yan TD, et al. Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications. Ann Cardiothorac Surg. 2017;6:298\u2013306.","journal-title":"Ann Cardiothorac Surg"},{"key":"961_CR8","doi-asserted-by":"crossref","unstructured":"Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS. Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy: an initial experience. J Am Heart Assoc. 2016;5.","DOI":"10.1161\/JAHA.115.002488"},{"key":"961_CR9","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.hrthm.2016.01.001","volume":"13","author":"PD Lambiase","year":"2016","unstructured":"Lambiase PD, Gold MR, Hood M, Boersma L, Theuns DAMJ, Burke MC, et al. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016;13:1066\u201374.","journal-title":"Heart Rhythm"},{"key":"961_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1540-8167.2007.00780.x","volume":"18","author":"YM Cha","year":"2007","unstructured":"Cha YM, Gersh BJ, Maron BJ, Boriani G, Spirito P, Hodge DO, et al. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2007;18:483\u20137.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"961_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/europace\/eur362","volume":"14","author":"C O\u2019Mahony","year":"2012","unstructured":"O\u2019Mahony C, Lambiase PD, Rahman SM, Cardona M, Calcagnino M, Quarta G, et al. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. Europace. 2012;14:724\u201333.","journal-title":"Europace."},{"key":"961_CR12","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu199","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379.","journal-title":"Eur Heart J"},{"issue":"8","key":"961_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/europace\/eut206","volume":"15","author":"M Brignole","year":"2013","unstructured":"Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013 Aug;15(8):1070\u2013118.","journal-title":"Europace."},{"key":"961_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0300-8932(10)70210-4","volume":"63","author":"R Barriales-Villa","year":"2010","unstructured":"Barriales-Villa R, Centuri\u00f3n-Inda R, Fern\u00e1ndez-Fern\u00e1ndez X, Ortiz MF, P\u00e9rez-Alvarez L, Rodr\u00edguez Garc\u00eda I, et al. Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2010;63:985\u20138.","journal-title":"Rev Esp Cardiol"},{"key":"961_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0735-1097(96)00473-1","volume":"29","author":"RA Nishimura","year":"1997","unstructured":"Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29:435\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"961_CR16","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/oxfordjournals.eurheartj.a015435","volume":"18","author":"L Kappenberger","year":"1997","unstructured":"Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J. 1997;18:1249\u201356.","journal-title":"Eur Heart J"},{"key":"961_CR17","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1161\/01.CIR.99.22.2927","volume":"99","author":"BJ Maron","year":"1999","unstructured":"Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99:2927\u201333.","journal-title":"Circulation."},{"key":"961_CR18","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1161\/01.CIR.0000145610.64014.E4","volume":"110","author":"MS Wathen","year":"2004","unstructured":"Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, et al. PainFREERx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies(PainFREERxII) trial results. Circulation. 2004;110:2591\u2013625.","journal-title":"Circulation"},{"key":"961_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.hrthm.2020.02.024","volume":"17","author":"PD Dallaglio","year":"2020","unstructured":"Dallaglio PD, di Marco A, Moreno Weidmann Z, Perez L, Alzueta J, Garc\u00eda-Alberola A, et al. Antitachycardia pacing for shock prevention in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Heart Rhythm. 2020;17:1084\u201391.","journal-title":"Heart Rhythm"},{"key":"961_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2008.05.011","volume":"52","author":"BL Wilkoff","year":"2008","unstructured":"Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52:541\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"961_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1056\/NEJMoa1211107","volume":"367","author":"AJ Moss","year":"2012","unstructured":"Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:275\u201383.","journal-title":"N Engl J Med"},{"key":"961_CR22","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2013.4598","volume":"309","author":"M Gasparini","year":"2013","unstructured":"Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309:1903\u201311.","journal-title":"JAMA"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-021-00961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-021-00961-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-021-00961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T02:06:20Z","timestamp":1642039580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-021-00961-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1007\/s10840-021-00961-9","relation":{},"ISSN":["1383-875X","1572-8595"],"issn-type":[{"value":"1383-875X","type":"print"},{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"16 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.T.R. is a member of the Medtronic European Advisory Board. Has received training course fees from Medtronic, Abbott, and Boston. All other authors did not have a conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}